Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer
Beiträge zur Klinik der Tuberkulose und spezifischen Tuberkulose-Forschung - Tập 201 - Trang 489-497 - 2023
Tóm tắt
Chimeric antigen receptor T cell (CAR-T) therapy stands as a precise and targeted approach in the treatment of malignancies. In this study, we investigated the feasibility of targeting Cadherin 17 (CDH17) with CDH17 CAR-T cells as a therapeutic modality for small cell lung cancer (SCLC). CDH17 expression levels were assessed in human SCLC tumor tissues and cell lines using qPCR and Western blot. Subsequently, we established CDH17 CAR-T cells and assessed their cytotoxicity by co-culturing them with various SCLC cell lines at different effector-to-target (E:T) ratios, complemented by ELISA assays. To ascertain the specificity of CDH17 CAR-T cells, we conducted experiments on SCLC cells with and without CDH17 expression (shRNAs). Furthermore, we employed an SCLC xenograft model to evaluate the in vivo efficacy of CDH17 CAR-T cells. Our results revealed a significant upregulation of CDH17 in both SCLC tissues and cell lines. CDH17 CAR-T cells exhibited robust cytotoxic activity against SCLC cells in vitro, while demonstrating no cytotoxicity towards CDH17-deficient SCLC cells and HEK293 cells that lack CDH17 expression. Importantly, the production of IFN-γ and TNF-α by CDH17 CAR-T cells correlated with their cytotoxic potency. Additionally, treatment with CDH17 CAR-T cells significantly decelerated the growth rate of SCLC-derived xenograft tumors in vivo. Remarkably, no significant difference in body weight was observed between the control group and the group treated with CDH17 CAR-T cells. The preclinical data open further venues for the clinical use of CDH17 CAR-T cells as an immunotherapeutic strategy for SCLC treatment.
Tài liệu tham khảo
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A (2021) Epidemiology of lung cancer. Contemp Oncol (Pozn) 25:45–52. https://doi.org/10.5114/wo.2021.103829
Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366:1385–1396. https://doi.org/10.1016/S0140-6736(05)67569-1
Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, Schild SE (2013) The first survival score for patients with brain metastases from small cell lung cancer (SCLC). Clin Neurol Neurosurg 115:2029–2032. https://doi.org/10.1016/j.clineuro.2013.06.019
Wang M, Herbst RS, Boshoff C (2021) Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 27:1345–1356. https://doi.org/10.1038/s41591-021-01450-2
Yang WC, Hsu FM, Yang PC (2020) Precision radiotherapy for non-small cell lung cancer. J Biomed Sci 27:82. https://doi.org/10.1186/s12929-020-00676-5
Fuca G, Reppel L, Landoni E, Savoldo B, Dotti G (2020) Enhancing chimeric Antigen receptor T-Cell efficacy in solid tumors. Clin Cancer Res 26:2444–2451. https://doi.org/10.1158/1078-0432.CCR-19-1835
Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11:69. https://doi.org/10.1038/s41408-021-00459-7
Gessner R, Tauber R (2000) Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci 915:136–143. https://doi.org/10.1111/j.1749-6632.2000.tb05236.x
Lee HJ, Nam KT, Park HS, Kim MA, Lafleur BJ, Aburatani H, Yang HK, Kim WH, Goldenring JR (2010) Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology 139:213–225e213. https://doi.org/10.1053/j.gastro.2010.04.008
Ko S, Chu KM, Luk JM, Wong BW, Yuen ST, Leung SY, Wong J (2004) Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochem Biophys Res Commun 319:562–568. https://doi.org/10.1016/j.bbrc.2004.04.197
Panarelli NC, Yantiss RK, Yeh MM, Liu Y, Chen YT (2012) Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol 138:211–222. https://doi.org/10.1309/AJCPKSHXI3XEHW1J
Takamura M, Ichida T, Matsuda Y, Kobayashi M, Yamagiwa S, Genda T, Shioji K, Hashimoto S, Nomoto M, Hatakeyama K, Ajioka Y, Sakamoto M, Hirohashi S, Aoyagi Y (2004) Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett 212:253–259. https://doi.org/10.1016/j.canlet.2004.03.016
Wang XQ, Luk JM, Garcia-Barcelo M, Miao X, Leung PP, Ho DW, Cheung ST, Lam BY, Cheung CK, Wong AS, Lau SS, So MT, Yu WC, Cai Q, Liu KS, Hui CK, Lau GK, Poon RT, Wong J, Fan ST (2006) Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin Cancer Res 12:5248–5252. https://doi.org/10.1158/1078-0432.CCR-06-0558
Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TPF, Schrader J, Metz DC, June CH, Hua X (2022) Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nat Cancer 3:581–594. https://doi.org/10.1038/s43018-022-00344-7
Garcia-Martinez JM, Wang S, Weishaeupl C, Wernitznig A, Chetta P, Pinto C, Ho J, Dutcher D, Gorman PN, Kroe-Barrett R, Rinnenthal J, Giragossian C, Impagnatiello MA, Tirapu I, Hilberg F, Kraut N, Pearson M, Kuenkele KP (2021) Selective Tumor Cell apoptosis and Tumor Regression in CDH17-Positive colorectal Cancer models using BI 905711, a Novel Liver-Sparing TRAILR2 agonist. Mol Cancer Ther 20:96–108. https://doi.org/10.1158/1535-7163.MCT-20-0253
Kusano-Arai O, Iwanari H, Kudo S, Kikuchi C, Yui A, Akiba H, Matsusaka K, Kaneda A, Fukayama M, Tsumoto K, Hamakubo T (2018) Synergistic cytotoxic effect on gastric Cancer cells of an Immunotoxin Cocktail in which antibodies recognize different epitopes on CDH17. Monoclon Antib Immunodiagn Immunother 37:1–11. https://doi.org/10.1089/mab.2017.0043
Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M (2022) Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 19:342–355. https://doi.org/10.1038/s41571-022-00607-3
Cruz E, Kumar S, Yuan L, Arikkath J, Batra SK (2018) Intracellular amyloid beta expression leads to dysregulation of the mitogen-activated protein kinase and bone morphogenetic protein-2 signaling axis. PLoS ONE 13:e0191696. https://doi.org/10.1371/journal.pone.0191696
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283–1298. https://doi.org/10.1016/j.cell.2006.01.040
He P, Tan Z, Wei Z, Wan CL, Yang SS (2020) Co-expressing LRP6 with Anti-CD19 CAR-T cells for Improved Therapeutic Effect Against B-ALL. Front Oncol 10:1346. https://doi.org/10.3389/fonc.2020.01346
Perry JL, Reuter KG, Luft JC, Pecot CV, Zamboni W, DeSimone JM (2017) Mediating Passive Tumor Accumulation through particle size, tumor type, and location. Nano Lett 17:2879–2886. https://doi.org/10.1021/acs.nanolett.7b00021
Kosti P, Maher J, Arnold JN (2018) Perspectives on chimeric Antigen receptor T-Cell immunotherapy for solid tumors. Front Immunol 9:1104. https://doi.org/10.3389/fimmu.2018.01104
Liu X, Huang Y, Yuan H, Qi X, Manjunath Y, Avella D, Kaifi JT, Miao Y, Li M, Jiang K, Li G (2019) Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Cancer Lett 454:204–214. https://doi.org/10.1016/j.canlet.2019.04.022